Medtronic, a medical technology company, has won CE mark approval for its Viva/Brava cardiac resynchronisation therapy devices.
The Viva/Brava portfolio of cardiac resynchronisation therapy with defibrillation (CRT-D) feature AdaptivCRT, a new algorithm which by preserving the patients’ normal heart rhythms and by continuously adapting to individual patient needs, improves heart failure patients’ response rate to CRT-D therapy.
Massachusetts General Hospital in Boston cardiac resynchronisation programme director Dr Jagmeet P Singh said that while CRT is an effective therapy which reduces hospitalisation rates, treatment must be tailored to the patient.
"The new AdaptivCRT technology is designed to improve CRT response by automatically providing a new way to deliver and dynamically optimise therapy, offering each patient individualised treatment," said Singh.
AdaptivCRT continually adjusts to the patient’s dynamic intrinsic conduction, and enables more natural contractions as it synchronises ventricular contraction, according to Medtronic.
The Viva/Brava CRT devices, which are designed to reduce skin pressure by 30% compared to most other CRT devices, feature the Ensure CRT suite with Cardiosync in-office optimisation, which works to maximise CRT treatment, even during atrial fibrillation.
SmartShock Technology implemented in the devices recognises life-threatening arrhythmias but delivers therapeutic shocks only when appropriate, while OptiVol 2.0 fluid status monitoring measures changes in fluid build-up in heart failure patients to identify patients at risk of worsening heart failure.
Medtronic senior vice president and Cardiac Rhythm Disease Management business president Pat Mackin said; "AdaptivCRT enables us to deliver CRT differently, allowing for greater efficiency and ensuring maximum treatment response."
Image: Medtronic Viva/Brava cardiac resynchronisation therapy devices will improve response rate to lifesaving therapy. Photo: Courtesy of Bobak Ha’Eri.